BP invests $5 billion in Tiber-Guadalupe offshore project in the Gulf of Mexico, targeting first production in 2030 and aiming to boost regional output.
AstraZeneca proposes a direct NYSE listing to broaden its global investor base and simplify access for U.S. investors, while the company's Enhertu drug shows promising results.
BP invests $5 billion in Tiber-Guadalupe offshore project in the Gulf of Mexico, targeting first production in 2030 and aiming to boost regional output.
AstraZeneca proposes a direct NYSE listing to broaden its global investor base and simplify access for U.S. investors, while the company's Enhertu drug shows promising results.